Welcome
Support Centre
18 April 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
DEPression in Visual Impairment Trial
ISRCTN ISRCTN46824140
DOI 10.1186/ISRCTN46824140
ClinicalTrials.gov identifier
EudraCT number
Public title DEPression in Visual Impairment Trial
Scientific title DEPression in Visual Impairment Trial
Acronym DEPVIT
Serial number at source N/A
Study hypothesis The National Institute for Health and Clinical Excellence (NICE) recommends screening high risk groups for depression and providing treatment according to the ‘stepped care’ framework.
However, although there are good reasons for believing that the prevalence of depression is high in people who access low vision rehabilitation services, screening and referral for treatment is not currently part of the service.

This study aims to establish depression screening and referral for treatment in two centres to:
1. Estimate the prevalence of depressive symptoms in consecutive attendees of low vision services in England and Wales
2. Compare three interventions for newly-diagnosed low vision patients with depressive symptoms in an exploratory randomised controlled trial

We also aim to obtain preliminary information about the cost effectiveness of our interventions.
Lay summary Lay summary under review 3
Ethics approval South East Wales Research Ethics Comittee, 4 May 2011 ref: 11/WA/0014
Substanital Amendment No.1 approved 20 September 2011
Study design Observational exploratory multi-centre two arm and waiting list control randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Visual Impairment and depression
Participants - inclusion criteria 1. Adults (aged at least 18 years)
2. Score of at least 6 on the GDS-15 (administered as part of the routine pre assessment questionnaire)
Participants - exclusion criteria 1. Those who have already had a low vision assessment within the previous 12 months
2. Those who are referred to the clinic in error (i.e. so visually impaired that low vision care and follow up are inappropriate or, so visually able (e.g. following refraction) that there are no low vision needs)
3. Those already being treated for depression including psychotherapeutic and psychopharmacological treatments
4. Inability to understand English
5. Inability to use the telephone e.g. caused by very poor hearing
6. Severe medical illness that would preclude participation in a 6 month study
7. A score of 2 or 3 on the BDI-II question about suicidal ideation. All people in this group will be urgently referred to their GP (See Appendix N for referral protocol)
8. Those screening positive for significant cognitive / memory problems will be excluded (see Appendix I for cognitive screening instrument / scoring key)
Anticipated start date 01/11/2011
Anticipated end date 30/04/2014
Status of trial Ongoing
Patient information material http://www.cardiff.ac.uk/optom/research/researchprojects/depvit/depvit.html
Target number of participants 1000 attendees will be screened, anticipated 1/3 will be eligible, of those, about 100 will consent to take part (recruitment will be capped at 150)
Interventions This trial includes three interventions:
1. Waiting list control
The control arm of this trial will be a follow up low vision assessment 6 weeks after the initial visit (follow up appointments of this type are typical for people who appear depressed or are obviously struggling at the initial low vision assessment) and, referral to the GP stating that the patient has symptoms of depression after the 6 month outcome measure i.e. this is a ‘waiting list control’.

2. Referral letter
A follow up low vision assessment visit at 6 weeks plus a letter to the patient’s GP , within 2 weeks of randomisation, informing them that their patient has screened positive for a possible depressive disorder and inviting them to offer the patient an assessment and treatment as per the NICE Guidelines for the management of depression. This is a pragmatic intervention and we acknowledge that GPs may or may not adhere to NICE guidelines i.e. we propose to evaluate the impact of the referral, not ‘best practice’ as described by NICE.

3. Problem Solving Treatment (PST)
A follow up low vision assessment visit 6 weeks plus a “problem-solving psychological treatment” based on that described by Rovner, Casten et al, (2007). Briefly, this involves a trained psychological therapist working with the patient in their own home or at one of the research centres. Over a 6-8 week period, patients are taught a 7-step method for approaching and solving their problems. The steps are:
3.1. Defining the problem
3.2. Establishing realistic goals
3.3. Brainstorming possible solutions and evaluating the pros and cons of each
3.4. Implementing decision making guidelines
3.5. Choosing a preferred solution
3.6. Implementing the solution
3.7. Evaluating the outcome

The first PST session will take place within 2 weeks of randomisation. The PST intervention will also include additional self-help materials for patients e.g. materials concerning an explanation of depression, a discussion on the importance of treating depression, and a description of the various treatment options as well as vision related sign posting materials.

The follow up period is 6 months.

We are also estimating the prevalence of depression in people attending Low Vision Clinics.
Primary outcome measure(s) Trial outcomes will be assessed by telephone at the baseline interview, immediately before randomisation, and then again at 3 and 6 months after randomisation.

1. At 3 months, participants in all arms of the study will be interviewed using five outcome measures:
1.1. The Beck Depression Inventory (BDI-II)
1.2. The 7 item Visual Function Questionnaire (7 item NEI-VFQ)
1.3. Near vision subscale of the VFQ-48
1.4. The EQ-5D
1.5. ICECAP capability measures

2. At 6 months the same outcome measures will be used again along with:
2.1. GDS-15
2.2. Client Services Receipt Inventory (CSRI)
In order to minimise ‘loss to follow up’, interviews will be based on a standard script and will remind participants of their valuable contribution and the need to complete the study.

3. In the exploratory randomised trial the primary outcome measure will be the change in depressive symptoms at 3 and 6 months (before randomisation – 3 & 6 months after randomisation) as measured by the BDI-II. These time intervals were chosen to:
3.1. Examine the short and longer term effects of the interventions
3.2. Coincide with those used in previous studies (Rovner, Casten et al, 2007)
3.3. Minimise the chance that a subsequent depressive episode might impact on outcomes
Secondary outcome measure(s) 1. Change in visual disability between baseline telephone interview and, 3 and 6 months as measured with the 7 item NEI VFQ (Ryan et al, 2008). We have recently used the 7 item NEI VFQ to evaluate functional ability outcomes in hospital and community based low vision services and it has shown itself to be a sensitive outcome measure (Court et al, 2010). Change in visual disability will also be evaluated using the near vision subscale of the VFQ-48 as used by Stelmack et al, (2008) in the LOVIT trial.
2. Change in ‘generic health related quality-of-life’ at 3 and 6 months as measured by the EQ-5D which assesses 5 health related dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression. NICE recommend the use of the EQ-5D, which can be used to calculate ‘utility’, as a standardised outcome measure.
3. The proportion of people still screening positive for depression as measured with the GDS-15 at 6 months.

At the end of the trial (6 months):
1. Participants will be asked about any treatments for depression they have received during the trial period (specifically, whether they received regular review and support by their GP, referral to a community mental health team, supportive psychotherapy, counselling, problem-solving therapy, cognitive-behavioural therapy or antidepressant therapy). They will also be asked about the acceptability of this intervention.
2. Participants in the PST arm will be asked about the acceptability of this intervention.
3. Participants in the waiting list control group who still screen positive for depression (GDS-15, 6+) will be referred to their GP. And, 3 months later asked about any treatment for depression received as a result of the referral (as per 1 above).
Sources of funding Guide Dogs for the Blind (UK) ref: OR2009-07b
Trial website http://www.cardiff.ac.uk/optom/depvit
Publications
Contact name Dr  Tom  Margrain
  Address School of Optometry and Vision Sciences
Cardiff University
Maindy Road
Cathays
  City/town Cardiff
  Zip/Postcode CF24 4LU
  Country United Kingdom
  Email margrainth@cardiff.ac.uk
Sponsor Cardiff University (UK)
  Address c/o Mr Chris Shaw
Research and Commercial Division
7th Floor
30-36 Newport Road
  City/town Cardiff
  Zip/Postcode CF24 0DE
  Country United Kingdom
  Sponsor website: http://www.cardiff.ac.uk/racdv/
Date applied 12/10/2011
Last edited 27/06/2012
Date ISRCTN assigned 21/12/2011
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.